|Bid||82.42 x 30000|
|Ask||82.46 x 50000|
|Day's Range||81.59 - 81.85|
|52 Week Range||71.00 - 89.07|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Fresenius Medical (FMS) is banking on its Growth Strategy 2020 plan for gaining market traction in the future. However, lackluster performance in the bourse is a concern.
In addition to selling dialysis products, Fresenius Medical Care also offers dialysis treatment and associated laboratory services to patients through its network of 3,690 clinics.
In 1H17, Fresenius Medical Care (FMS) earned ~1.6 billion euros from the sale of dialysis products, which equals year-over-year growth of 8% on a reported basis.
In 2Q17, Fresenius Medical Care (FMS) reported revenues close to 3.3 billion euros, which represents year-over-year growth of ~11%.
For fiscal 2017, Wall Street analysts have projected Fresenius Medical Care’s net profit margins to be close to 6.2%, which is a YoY decline of ~70 basis points.
For fiscal 2017, Wall Street analysts have projected Fresenius Medical Care’s revenues to be close to $20.8 billion, which equals YoY growth of ~16.0%.
In 1H17, Fresenius Medical Care (FMS) reported revenues close to 9.0 billion euros, which represents 14% YoY growth. At the end of 2Q17, the company operated 3,690 dialysis clinics around the world.
Fresenius’s minority-owned kidney dialysis business agreed to acquire NxStage Medical Inc. for about $2 billion.
German dialysis provider Fresenius Medical Care (FMS) announced that it will acquire U.S. home dialysis device maker NxStage Medical, Inc. (NXTM) for $2 billion.
German dialysis provider Fresenius Medical Care has agreed to buy U.S. home dialysis device maker NxStage for around $2 billion in cash, FMC said in a statement on Monday. FMC said the acquisition would ...
Despite margin contraction in the Dialysis and Care Coordination segments, Fresenius Medical Care (FMS) posted a strong second quarter on solid growth in Asia Pacific and Latin America.
On Jul 11, we issued an updated research report on Bad Homburg, Germany-based Fresenius Medical Care (FMS), one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure.
Rating Action: Moody's upgrades FMCH's long term issuer rating to Baa3, outlook stable. Global Credit Research- 07 Jul 2017. Frankfurt am Main, July 07, 2017-- Moody's Investors Service, has today upgraded ...
The Bad Homburg, Germany-based company said it had profit of 53 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Last week, Fresenius Kabi, a subsidiary of Fresenius Medical Care AG & Co. (ADR) (NYSE: FMS ) said it was looking into the possibility of acquiring Akorn, Inc. (NASDAQ: AKRX ). Since the announcement, ...
BAD HOMBURG, GERMANY / ACCESSWIRE / April 10, 2017 / Fresenius Medical Care AG & Co. KGaA ("the company" or "Fresenius Medical Care"), the world's largest provider of dialysis products ...
Akorn Therapeutics stock launched to a six-month high midday Friday, outperforming other generic drugmakers.
Fresenius Medical Care AG & Co. KGAA announced the acquisition of 70% equity interest in Kunming Wuhua Health Hospital in China.